Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2025 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next...
September 03, 2024 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences...
August 19, 2024 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...
July 30, 2024 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)...
July 17, 2024 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next...
April 11, 2024 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more...
February 06, 2024 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...